Intuitive Surgical, Inc. — FY2010 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2010. Intuitive Surgical designs, manufactures, and markets da Vinci robotic surgical systems, instruments, accessories, and related service. It operates as one business segment. Its model combines system sales with recurring instrument, accessory, and service revenue.
Financial performance and position
| Metric | FY2010 | FY2009 |
|---|---|---|
| Revenue | $1,413.0 million | $1,052.2 million |
| Gross profit / margin | $1,030.0 million / 73% | $751.1 million / 71% |
| Operating income / margin | $555.2 million / 39% | $377.4 million / 36% |
| Net income / diluted EPS | $381.8 million / $9.47 | $232.6 million / $5.93 |
| Cash from operations | $528.0 million | $385.1 million |
| Cash, cash equivalents, and investments | $1,608.9 million | $1,172.0 million |
- Revenue rose 34%; system revenue increased 35% to $660.3 million, and instruments and accessories revenue grew 36% to $528.8 million. Service revenue was $223.9 million.
- Recurring revenue increased 34% to $752.7 million, or 53% of total revenue, from $561.7 million, or 53%, in 2009.
- Approximately 278,000 procedures were performed, up about 35%. The installed base grew to 1,752 systems from 1,395.
- Gross margin improved to 73% from 71%, reflecting higher system selling prices, lower material costs, lower inventory charges, and manufacturing leverage. Operating income rose 47%; net income rose about 64%.
- Capital allocation included $198.6 million of share repurchases and $96.0 million for capital expenditures and intellectual property. The company ended 2010 with $2,037.4 million in equity and $353.0 million in total liabilities. The balance sheet does not present a separate interest-bearing debt balance.
- Fourth-quarter 2010 revenue was $389.3 million and net income was $121.2 million, versus $323.1 million and $77.5 million, respectively, in fourth-quarter 2009.
Material changes versus prior period
- System sales increased to 441 from 338, including 372 da Vinci Si systems; average system selling price rose to $1.44 million from $1.39 million.
- Procedure growth broadened: hysterectomy volume rose to about 110,000 from 69,000, while prostatectomy volume increased to about 98,000 from 90,000. Other procedures grew more than 50% to about 70,000.
- Operating cash flow increased to $528.0 million from $385.1 million. Cash and investments grew by $436.9 million; employee stock programs generated $141.1 million, partly offset by repurchases and investment spending.
- SG&A rose 29% to $358.8 million and R&D rose 22% to $116.0 million, as the company expanded sales, service, and development teams.
Outlook, risks, contingencies, and unusual items
- Management gave no specific revenue or earnings guidance. It expects recurring revenue to become a larger share of total revenue, plans continued substantial R&D investment, and expects to fund future growth from operating cash flow. Management said existing cash and investments, together with expected product sales, should meet liquidity needs for the foreseeable future.
- Key business risks include adoption and reimbursement uncertainty, competition, lengthy and seasonal hospital capital-sales cycles, product quality and liability exposure, manufacturing and sole-source supplier risks, and international and foreign-exchange risks.
- Japan sales remain dependent on procedure reimbursement approvals; 13 systems were sold there in 2010, primarily to early adopters. The filing warns that lack of reimbursement or future product and procedure approvals could constrain demand.
- The FDA’s July 2010 inspection resulted in a Form 483 identifying quality-system deficiencies involving complaint handling and manufacturing/inspection handling. The company submitted proposed corrective actions but could not assure their adequacy or implementation.
- A purported securities class action and two derivative actions concern alleged misleading disclosures from 2008–2009. The company reported that it could not estimate the outcomes and accrued no amounts; it believed the cases were unlikely to have a material adverse effect.
- The company held $18.6 million of illiquid auction-rate securities at year-end, with failed auctions since 2008 and a $4.0 million unrealized loss. No impairment charge was recorded. It also disclosed $78.9 million in gross unrecognized tax benefits.
- Healthcare reform included a 2.3% excise tax on certain U.S. medical-device revenue beginning in 2013. Management said the effects of reform and comparative-effectiveness research remained uncertain.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.
Investor verification priorities
- Assess whether procedure growth—especially benign hysterectomy growth—and utilization per installed system are sustainable, and whether recurring revenue continues to expand.
- Verify the clinical evidence, reimbursement status, and economics supporting adoption across procedures and markets, particularly Japan.
- Track remediation and subsequent FDA inspection outcomes related to the 2010 Form 483 observations.
- Monitor the shareholder litigation, related disclosures, and any eventual financial or governance consequences.
- Review the valuation and liquidity of the remaining auction-rate securities and developments in tax positions and unrecognized tax benefits.
- Evaluate the impact of rising sales, service, and R&D costs, stock-based compensation, and the 2013 medical-device excise tax on future margins and cash generation.